Navigation Links
Lymphoma's Link to Hepatitis C

Researchers at the University of Hopkins found a new study shows some cancer patients who also have the hepatitis C virus may benefit from treatment with the drug, interferon. Past research has suggested a connection between the hepatitis C virus and some B-cell non-Hodgkin's lymphoma's. //A patient with both of these diseases was treated with the antiviral treatment interferon. The patient responded causing researchers in Paris to study whether the treatment could help other patients with a similar diagnosis.

Nine patients who had splenic lymphoma with villous lymphocytes, a specific type of B-cell non-Hodgkin's lymphoma, and the hepatitis C virus infection were treated with interferon either alone or in combination with the drug, ribavirin. Outcomes of these patients were then compared to six similarly treated patients with splenic lymphoma with villous lymphocytes who did not have the hepatitis C virus infection.

Researchers report seven of the patients treated with interferon had a complete remission of their cancer. The other two patients had a partial and complete remission after the addition of ribavirin was added to their treatment. In contrast, none of the six patients without the hepatitis C virus responded to the interferon therapy.

Researchers felt that in patients with splenic lymphoma with villous lymphocytes who are infected with the hepatitis C virus, treatment with interferon can lead to remission of the lymphoma.


'"/>




Page: 1

Related medicine news :

1. Vitamin B for Hepatitis
2. Hepatitis G May Boost HIV Survival
3. Cure for Hepatitis B
4. Hepatitis E virus made impotent
5. Sharing injection equipment spreads Hepatitis C
6. Hepatitis shots is promising
7. Need for Hepatitis Booster Questioned
8. Good News for HIV Patients Also Suffering From Hepatitis C Virus
9. The Link Between Hepatitis B Vaccine And Multiple Sclerosis Questioned
10. The Effectiveness Of Hepatitis B Vaccine Questioned
11. New Treatment for Chronic Hepatitis B
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... whiteboard display solutions, proudly announced today that a new solution for Emergency Departments ... fit in the tight space in Emergency Department examination rooms, and with a ...
(Date:12/8/2016)... Cambridge, MA (PRWEB) , ... December 08, 2016 ... ... the Workers Compensation Research Institute (WCRI) officially opened registration today for its ... Place Hotel in Boston, MA . , The theme of the conference is ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s leading digital ... aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced CURE Media ... Jr said, “CURE Media Group is honored to team up with Upstage Lung Cancer ...
(Date:12/8/2016)... (PRWEB) , ... December 08, ... ... Presence Suite 10.2 version gives development continuity to its innovative Unified Instance ... channels management capacity. In addition, this new version optimizes the unattended auto-dialing ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged ... in mind, SIGVARIS has created a new line of anti-embolism stockings to help ... provide the benefits of graduated compression when transitioning from recovery to early rehabilitation. ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016 KEY FINDINGS ... of the market in 2016 and is expected to ... attributed to a large number of surgical procedures that ... largest share in the patient temperature management market.) Patient ... reducing loss of blood during surgeries, lowering the risks ...
(Date:12/8/2016)... Research and Markets has announced the addition ... Adhesion Type, Application, Usability - Forecast to 2025" report to ... , , ... poised to grow at a CAGR of around 3.2% from 2015 ... witnessing include advancements in extracellular microelectrode arrays and intracellular microelectrodes, research ...
(Date:12/8/2016)... 2016  Valeant Pharmaceuticals International, Inc. (NYSE: ... announced positive results from a Phase 3, multicenter ... safety and efficacy of IDP-118 (halobetasol propionate and ... Within the Phase 3 study ... psoriasis, IDP-118 showed statistical significance to vehicle with ...
Breaking Medicine Technology: